Skip to content
10-K

Annual Report

IMMIX BIOPHARMA, INC. IMMX

0001641172-25-000387

← back to feed
Filed
Mar 25, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Stockholders Equity FY 2024 · Dec 31, 2024 $13.25M
Stockholders Equity FY 2024 · Dec 31, 2023 $16.41M
Shares Diluted FY 2024 · Dec 31, 2023 17.34M sh
Capex FY 2024 · Dec 31, 2023 $52.09K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$11.37M
Cash And Equivalents FY 2024 · Dec 31, 2023 $17.51M
Current Liabilities FY 2024 · Dec 31, 2023 $3.72M
Total Liabilities FY 2024 · Dec 31, 2023 $3.72M
Current Assets FY 2024 · Dec 31, 2023 $19.79M
Total Assets FY 2024 · Dec 31, 2023 $19.93M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.89
Eps Basic FY 2024 · Dec 31, 2023 −$0.89
Sga Expense FY 2024 · Dec 31, 2023 $7.41M
Rd Expense FY 2024 · Dec 31, 2023 $8.74M
Net Income FY 2024 · Dec 31, 2023 −$15.43M
Operating Income FY 2024 · Dec 31, 2023 −$16.14M